TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: risk of failure on the first attempt of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in ocular fundus parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of falciparum malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Nankivell GFR (mL/Min) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dose-normalized Tacrolimus 12-h-AUC (h/103*L) at Month 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global postoperative morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients with COVID-19 who Require ICU-Level Care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Requirement for Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cmax: Maximum Plasma Concentration of Lemborexant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-8 Hours): Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours Postdose of Lemborexant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-72 Hours): Area Under the Plasma Concentration-Time Curve From Time Zero to 72 Hours Postdose of Lemborexant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Absence Seizure Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Seizure-Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Global Impression of Improvement (CGI-I) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quantity and frequency of alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age of onset of first menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: number of symptomatic urinary tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Imaging parameters from MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Value of BC risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean annual FEV1 (% predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: acute graft versus host disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: chronic graft versus host disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: First recurrent suicide behavior
Endpoint domain: Mortality/survival
Primary endpoint: Safety of MIYA-BM
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary beta2microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Volume Change of Nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Thyroid Stimulating Hormone (TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ThyPRO 39 Survey Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Experiencing Relapse of Depression
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatitis B Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma PF-00868554 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine PF-00868554 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sinus opacifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Levels of TNFα
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incremental yield for dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute subjective appetite responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3-months deterioration free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of breastfeeding women during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of participants capable of completing the survey
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Tinnitus handicap inventory score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Days to healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and toxicity of allogeneic bone marrow transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Parental Sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Parenting Knowledge of Child Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of arrosion bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of thrombotic events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of bleedings related to anticoagulation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in average daily steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Range of motion (ROM) in affected shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Shared Decision Making (SDM) Process score
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Dose Limiting Doxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: pCO2 EVOLUTION
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Outcome of geriatric hip fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employment and Vocational Activities Checklist
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Work Hope Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brief Quality of Life Scale, Subjective Items
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patterns of arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Boston Bowel Preparation Scale (BPPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Aronchick scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normalization of fasting serum IGF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time taken to IGF-1 normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Steady-state Trough Serum Concentration (Cmin) of Abatacept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Daily Average of Moderate and Vigorous Physical Activity (MVPA) Levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increase in antibody titers against AI viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sinus Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline carotid-femoral Pulse Wave Velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Score on the WHO 11-point Ordinal Scale for Clinical Improvement at 14 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactivity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analytical measurement of 3D implant positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Small airway dysfunction evaluated by impulse oscillometry test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Small airway dysfunction evaluated by thorax computed tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Small airway dysfunction evaluated by body plethysmography test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptom control evaluated by asthma control test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of moderate and severe exacerbations over a 1 year period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tenofovir plasma area-under the concentration time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of overdue patients completing mammography screening
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Safety of 3rd party EBV-CTLs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in glucose AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women reporting inappropriate behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grade 4 or 5 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Event rate of over-expression of cyclooxygenase-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change of eicosanoid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change of VEGF and prostaglandin-M levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of gene and protein expression pattern from pre- to post-treatment levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VWF activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improved relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Reduced Emotional Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Academic/Social Skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in Acute Care Utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of procedure-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Entering Any Exercise Data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients Entering Resistance Data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fullness sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness measured by QIF score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Appearance of common respiratory infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Appearance of common gastrointestinal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: serum levels of n-3 to n-6 PUFA ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: regulatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Geometric Mean Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in frailty status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lower extremity physical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical Excitability MEP Amplitude (µV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortical Excitability Percentage of Maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and Tolerability of Sodium Phenylbutyrate
Endpoint domain: Adverse events/effects
Primary endpoint: Potential Efficacy of Sodium Phenylbutyrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in nighttime blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in CD4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Aberrant Behavior Checklist-Irritability Subscale (ABC-I)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of agreement (kappa co-efficient) between management decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of post-operative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Requirement of further antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of Peripheral Blood BCR-ABL/ABL Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in LogMar visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemorrhages or AMI frequency and proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in plasma total anthocyanin detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma Cyanidin-3-O-glucoside detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of IL-12
Endpoint domain: Adverse events/effects
Endpoint subdomain: Dose Limiting Toxicity (DLT)
Primary endpoint: Neuropsychomotor development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nicotine Craving Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy during facial expression recognition task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction times during facial expression recognition task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy during faces dot-probe task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction times during faces dot-probe task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy during emotional categorisation task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy during emotional recall task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of emtricitabine, tenofovir and efavirenz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of the tuberculostatic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in cholesterol specific biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects Who Had Hospitalization for Ventricular Tachycardia (VT) Related Causes/Events
Endpoint domain: Adverse events/effects
Primary endpoint: Epiphora grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tinetti Performance Oriented Mobility Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Perinatal Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in media viewing habits
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changes in exposure to violence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fecal microbial community structure and functional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stride distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sinus rhythm at end of follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of muscular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of gastric adenocarcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Ongoing pregnancy rate per embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants With Uterine Extension of Hysterotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Umbilical Artery Blood pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Deliveries After Which Neonate is Admitted to NICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Deliveries in Which Cord Blood Base Deficit is More Negative Than or Equal to Negative 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: APGAR at 5 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical agreement of T-Detect™ SARS-CoV-2 Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Grade 3 and Vaccine-related Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Vaccine-related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement score of the NPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cell counts in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Slope Change From Baseline for Pupil Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metal ion levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ki-67 proliferation index in T cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Reached at Least One Safety Milestone
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Week 24 in Brachial Artery Flow-mediated Vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trough concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of stricture-free eradication of dysplastic BE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in 24 hour mean Diastolic blood pressure (DBP) after a missed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mean DBP during the last 6 hours of the 24 hour dosing interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimum serum concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pathologic complete response rate in the breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence and severity of clinical findings on physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in vital signs measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional Change in Air Content (Delta Z, %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ejection Fraction (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral Oximetry (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Posttraumatic Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful removal of the uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum voriconazole trough concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Lesions Identified by PET-CT That Were Correctly Detected by PET-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lipid water composition and ratio of normal breasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Breast outcomes
Primary endpoint: The incidence rate of adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with very good partial response or better response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new-onset neurological injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes